Mia paca 2

Pancreatic cancer cell lines PANC-1 and MIA PaCa-2 and normal cell line (L-929) were purchased from the Korean Cell Bank (Seoul, Republic of Korea). PANC-1 and MIA PaCa-2 cells were cultured with DMEM high glucose containing 10% FBS and 1% penicillin/streptomycin (Biowest, Nuaillé, France). L-929 cells were grown using RPMI 1640 media supplemented with 10% fetal bovine serum (FBS), 2 μM L-glutamine, and 10,000 U/mL of penicillin/streptomycin (Biowest, Nuaillé, France). Cells were incubated at 37 °C and humidified in 5% CO₂ conditions (MCO-15AC, Sanyo, Osaka, Japan). Cell subculture was conducted at regular intervals of 2–3 days.

Mia PaCa-2 cells were from the Riken BioResource Centre (Ibaraki, Japan). KPK1345 (link), SKR146 (link), and SUIT-2 cells were from the Cell Resource Centre for Biomedical Research (Institute of Aging, Development and Cancer, Tohoku University, Miyagi, Japan). HCT 116, MDA-MB-435S, and RKO cells were from the ATCC (Manassas, VA, USA). CO115 and HeLa cells were kind gifts of Dr. John M. Mariadason (Ludwig Institute for Cancer Research, Melbourne, Australia) and Professor A. Horii (Department of Molecular Pathology, School of Medicine, Tohoku University, Miyagi, Japan), respectively. A human umbilical vein endothelial cell (HUVEC) line was from Takara Bio (Shiga, Japan). HeLa, KPK13, Mia PaCa-2, RKO, SKR1, and SUIT-2 cells were maintained in DMEM supplemented with 8% FBS (Biowest, Nuaille, France). CO115, HCT 116, and MDA-MB-435S cells were maintained in RPMI1640 supplemented with 8% FBS. HUVECs were maintained with an EGM-2 BulletKit with the provided supplements (BD, Franklin Lakes, NJ, USA).

Human pancreatic cancer cell lines (MIA PaCa-2 and PANC-1) were purchased from the American Type Culture Collection (ATCC, MD, VA, United States). MIA PaCa-2 and PANC-1 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (Biowest, MO, United States) and 1% antibiotic-antimycotic reagent (Gibco, MA, United States) at 37°C and 5% CO₂. Cells were treated with different concentrations of gemcitabine (Yuhan, Seoul, Korea) and ivermectin (Selleckchem, PA, United States).